If anyone misses contributory IgG factors associated with gluten sensitivity you can suffer with mind altering disorders for the rest of your life, and they will remain untreatable. Yes, we can fix the symptoms, but the mind disorder will remain misunderstood, undiagnosed, untreated, and refractory to casual care. Think: cytokine parade.
You know me, readers – I’m doing everything I can to stay on top of the rapidly evolving biomedical science. Testing matters. What I’m reporting in these brief updates was simply not available just a few years ago. I hate to miss a diagnosis and thereby perpetuate any suffering – and if I don’t use the best evidence, the best data, I’m either in denial or awash in group-think. This is the reason I’m switching to Cyrex Labs for immunity testing – using Array 3 as a baseline for IgG [etc] testing. I’ll be posting more on these new data points through the Holiday Season.
These biomedical testing details – including why: reasons for, and how: useful testing data/recommendation maps – remain available in world class order at the Gluten Summit Site for download in audio, pdf and video programs.
Brief: from the Array 3 Protocol Outline:
Negative serology should not necessarily reassure the clinician of neither negative immune activation nor pathology. Several reports show that in the majority of celiac patients antibodies to gliadin and transglutatminase may be negative.1, 2, 3 [see Refs below]
That if one doesn’t measure the specific antigenic activity the real diagnosis remains missed. Reality remains overlooked. New technology changes the face of psychiatry and the clinical intervention systems for commonplace brain disorders such as ADHD, depression and anxiety.
I’ll be meeting with Aristo Vojdani PhD, Chief Scientific Advisor for Cyrex, at ACAM in Palm Springs this week to learn and report more… Stay tuned.
1 Tursi A, Br Med J 2005 http://www.bmj.com/rapid-response/2011/10/30/seronegative-coeliac-disease-clinical-challenge
2 Tursi A, Brandimarte G, Giorgetti G, Gigliobianco A, Lombardi D, Gasbarrini G. Low prevalence of antigliadin and anti-endomysium antibodies in subclinical/silent coeliac disease. Am J Gastroenterol 2001; 96: 1507- 10
3 Tursi A, Brandimarte G, Giorgetti G. Prevalence of anti-tissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease. J Clin Gastroenterol 2003; 36: 219-221